GlassScriptPhysician profile
Ejaz Ahmed
NPI 1003841081
$3,433.94
in general payments reported to CMS, 2019-2025
16 companies · $229 in 2025
The $229 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $997 · 2020: $450 · 2021: $143 · 2022: $340 · 2023: $463 · 2024: $811 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,503.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $738.48 | 2019-2025 | Farxiga, Airsupra |
| Amgen INC. | $704.28 | 2019-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $400.55 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $386.47 | 2019-2021 | |
| Amarin Pharma, INC. | $275.61 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $249.58 | 2020-2023 | Xarelto |
| Lilly USA, LLC | $191.92 | 2020-2022 | |
| Ethicon US, LLC | $118.25 | 2019 | |
| Glaxosmithkline, LLC. | $114.53 | 2023 | |
| Merck Sharp & Dohme LLC | $103.93 | 2019 | |
| Novartis Pharmaceuticals Corporation | $51.94 | 2019-2020 | |
| Photonicare INC | $31.87 | 2024 | Otosight Middle Ear Scope |
| Kowa Pharmaceuticals America, INC. | $21.41 | 2025 | Zoryve |
| Medtronic, INC. | $19.39 | 2024 | Closurefast |
| Paratek Pharmaceuticals, INC. | $14.05 | 2023 | Nuzyra |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medline Industries LP | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ejaz Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.